N/A N=264 Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
Metastatic Cancers
Primary: Percentage of Participants With V600 BRAF Mutation Status — 41.3; 58.3; 0.4 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Traditional Balance vs Vibrotactile Feedback Training for Vestibular Rehabilitation
Traumatic Brain Injury · Vestibular Deficits
Primary: Berg Balance Scale — 45; 44; 48; 47 Units on a continuous scale
Phase 2 N=208 Code Status Video in the Intensive Care Unit: Video Assisted Patient Education
Critical Illness
Primary: 12 Question Resuscitation Status Survey (Question 4 Has 4 Sub-questions) — 6.5; 9 points
Phase 2 N=243 Selegiline Patch for Treatment of Nicotine Dependence
Tobacco Use Disorder
Primary: Expired-air Carbon Monoxide Confirmed Smoking Abstinence — 24; 25 participants not smoking
N/A N=87 Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Carcinoma, Hepatocellular
Primary: Dose Area Product (DAP) — 184.2; 137.4 Gy.cm2 — p=<.001
Phase 3 N=709 Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline of HbA1c After 24 Weeks of Treatment. — -0.53; -0.21; -0.58; -0.10 Percentage of HbA1c — p=0.0013
Phase 3 N=4,040 Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)
Rotavirus Gastroenteritis
Primary: Number of Participants With Any Severity of Rotavirus Gastroenteritis — 34; 109 Participants — p=<0.001
Phase 3 N=140 A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia
Anemia
Primary: Percentage of Participants Maintaining Their Mean Hb Concentration Within Plus/Minus (±) 1 Grams Per Deciliter (g/dL) of the Reference Range and Between 10.0 and 12.0…
Phase 2 N=189 S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 1.8; 1.3; 1.4; 1.4 Months
N/A N=14 A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Performance and Safety of an Antimicrobial Foam Transferring Dressing in Patients With Malignant Wounds
Malignant Wounds
Primary: Infection in the Wound (Signs of Clinical Infection) — 14 participants
Phase 3 N=79 Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
HIV · HBV
Primary: Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL — 100.0; 94.4 percentage of participants
Phase 2 N=130 Enemas Before Elective Cesarean Section
Complications After Cesarean Section
Primary: Number of Participants With Bowel Sounds — 23; 31 participants — p=0.15
Phase 4 N=34 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Efficacy of the Treatment Assessed With Visual Acuity Measured by ETDRS Charts. — 0.18; 0.36; 0.18 logMAR
N/A N=135 Postplacental Intrauterine Device Insertion: A Mixed Methods Assessment of Women's Experience
Contraception
Primary: Assessment of Women's Experiences With Ring Forceps Postplacental IUD Placement Through Semi-structured Interviews — 12; 7; 0; 2 participants
N/A N=110 Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs) — 31.8; 7.2 percentage of participants